REG - Oxford Biomedica PLC - Block listing Application

Oxford BioMedicaAnnouncement

10/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230510:nRSJ8638Ya&default-theme=true

RNS Number : 8638Y  Oxford Biomedica PLC  10 May 2023

 

 

 

Oxford Biomedica

Block listing Application

 

Oxford, UK - 10 May 2023: Oxford Biomedica plc ("Oxford Biomedica" or the
"Company") (LSE:OXB), a quality and innovation-led viral vector CDMO,
announces that applications have been made to the Financial Conduct Authority
and the London Stock Exchange for admission to (i) the Premium segment of the
Official List and (ii) to trading on the London Stock Exchange for a block
listing of 500,000 ordinary shares of 50 pence each (the "Ordinary Shares").

 

The Ordinary Shares are being reserved under a block listing and will be
issued from time to time pursuant to the following schemes:

 

·      OXB Long Term Incentive Plan (LTIP) (300,000 Ordinary Shares);

·      OXB Deferred Bonus Plan (DBP) (100,000 Ordinary Shares);

·      Save As You Earn (SAYE) (100,000 Ordinary Shares).

 

It is expected that admission of the Ordinary Shares will become effective on
15 May 2023. The Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com,
www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSFKLLBXELEBBF